NDA 022382 · Cosette
Sprix
Ketorolac Tromethamine · Nasal
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
May 14, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
238
46 Phase 3, 16 recruiting
FAERS reports
4,851
2,626 serious, 263 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. SPRIX ® is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients...
What it is approved for
From the label in effect Dec 5, 2024.
SPRIX is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. Limitations of Use Sprix is not for use in pediatric patients less than 2 years of age. SPRIX is a nonsteroidal anti-inflammatory drug indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. ( 1 )
Mechanism: Ketorolac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of SPRIX, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2), an early component of the arachidonic acid cascade, resulting in the reduced synthesis of prostaglandins, thromboxanes, and prostacyclin. Ketorolac is a potent inhibitor of prostaglandin synthesis in vitro . Ketorolac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 14, 2010 Original approval · Type 3 - New Dosage Form LabelReviewSummary Review
1 products under this application
- SPRIX · KETOROLAC TROMETHAMINE 15.75MG/SPRAY · SPRAY, METERED, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ketorolac Tromethamine" as an intervention, any sponsor and status, largest first.
- Effectiveness of Periocular Drug Injection in CATaract SurgeryPivotal-lookingTerminated
Luigi RondasAcademic, hospital or other
NCT05158699 · 628 participants · Start Oct 13, 2021 · Primary completion Aug 13, 2024
Drug: Bromfenac; Dexamethasone and 2 more · For: Macular Edema; Cystoid Macular Edema; Retinal Disease and 3 more
Sites: Vienna, Austria; Frankfurt am Main, Germany; Breda, Netherlands · 10 sites in all
- Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal PainPivotal-lookingRecruiting
University of CalgaryAcademic, hospital or other
NCT06160778 · 495 participants (planned) · Start May 27, 2024 · Primary completion Jan 2029
Drug: Ketorolac Tromethamine; Morphine Sulfate and 2 more · For: Acute Pain; Abdomen, Acute; Abdominal Pain and 3 more
Sites: Calgary, Canada
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma PatientsPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06201676 · 458 participants (planned) · Start Feb 28, 2025 · Primary completion Dec 31, 2026
Drug: Ketorolac Injection · For: Orthopaedic Trauma; Chronic Opioid Use
Sites: Boston, Massachusetts; Nashville, Tennessee
- Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)Pivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT01789216 · 450 participants · Start Jul 2013 · Primary completion Dec 31, 2018
Drug: NSAID; Gabapentinoids and 1 more · For: Orthopaedic Fractures
Sites: Miami, Florida; West Palm Beach, Florida; Indianappolis, Indiana · 17 sites in all
- Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee InjectionsPivotal-lookingStatus unknown
St. Luke's Hospital, PennsylvaniaAcademic, hospital or other
NCT02612272 · 448 participants (planned) · Start Nov 2015 · Primary completion Oct 2017
Drug: Ketorolac; Betamethasone · For: Knee Osteoarthritis
Sites: Bethlehem, Pennsylvania
- Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic OperationsPivotal-lookingCompleted
Darnitsa Pharmaceutical CompanyIndustry
NCT05607641 · 424 participants · Start Jul 7, 2021 · Primary completion May 7, 2022
Drug: Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets; Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets and 1 more · For: Postsurgical Pain
Sites: Chernivtsi, Ukraine; Dnipro, Ukraine; Kharkiv, Ukraine · 14 sites in all
- Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationPivotal-lookingCompleted
Omeros CorporationIndustry
NCT01579565 · 416 participants · Start Apr 2012 · Primary completion Nov 2012
Drug: OMS302; Placebo · For: Intraocular Lens Replacement
Sites: Chandler, Arizona; Los Angeles, California; Fort Myers, Florida · 14 sites in all
- Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationPivotal-lookingCompleted
Omeros CorporationIndustry
NCT01454063 · 405 participants · Start Sep 2011 · Primary completion Mar 2012
Drug: OMS302; Placebo · For: Intraocular Lens Replacement
Sites: Chandler, Arizona; Glendale, Arizona; Los Angeles, California · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective524
- drug hypersensitivity301
- nausea272
- headache263
- pain250
- dyspnoea231
- fatigue226
- treatment failure205
- off label use202
- vomiting176
- diarrhoea156
- product dose omission issue148
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 43 |
| 2005 | 70 |
| 2006 | 69 |
| 2007 | 64 |
| 2008 | 83 |
| 2009 | 98 |
| 2010 | 99 |
| 2011 | 166 |
| 2012 | 201 |
| 2013 | 63 |
| 2014 | 83 |
| 2015 | 109 |
| 2016 | 431 |
| 2017 | 284 |
| 2018 | 262 |
| 2019 | 369 |
| 2020 | 504 |
| 2021 | 239 |
| 2022 | 310 |
| 2023 | 372 |
| 2024 | 345 |
| 2025 | 346 |
| 2026 | 241 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sprix (Ketorolac Tromethamine)
2024 spending
$2.0M
Beneficiaries
191
735 claims
Per beneficiary
$10,242
$503.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,866,365 |
| 2021 | $1,460,825 |
| 2022 | $1,666,491 |
| 2023 | $2,194,016 |
| 2024 | $1,956,284 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation.
Arruda MP, Lima RV, Hira S, et al. · Am J Ophthalmol 2024 · Meta-Analysis, Systematic Review
- Ketorolac tromethamine.
· Med Lett Drugs Ther 1990 · Clinical Trial
- The use of ketorolac in the management of postoperative pain.
DeAndrade JR, Maslanka M, Maneatis T, et al. · Orthopedics 1994 · Clinical Trial, Controlled Clinical Trial
- Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis.
Nurathirah MN, Yazid MB, Norhayati MN, et al. · Acad Emerg Med 2022 · Meta-Analysis, Systematic Review
- Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.
Motov S, Yasavolian M, Likourezos A, et al. · Ann Emerg Med 2017 · Comparative Study, Randomized Controlled Trial
- Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery.
Sivaprasad S, Bunce C, Crosby-Nwaobi R · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.